Semaglutide Reduces Body Weight vs. Dulaglutide across Baseline BMI Subgroups in SUSTAIN 7

Semaglutide Reduces Body Weight vs. Dulaglutide across Baseline BMI Subgroups in SUSTAIN 7

Semaglutide, a new GLP-1 analog for the treatment of T2D, showed significant and clinically meaningful reductions in HbA1c and body weight (BW) across the SUSTAIN clinical trial program. SUSTAIN 7 compared semaglutide vs. dulaglutide (both once weekly) head-to-head in subjects with T2D both as add-o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2018-07, Vol.67 (Supplement_1)
Hauptverfasser: VILJOEN, ADIE, BLUHER, MATTHIAS, CHOW, FRANCIS C.C., ROUX, CAREL LE, ROSENSTOCK, JULIO, LAUSVIG, NANNA L., YILDIRIM, EMRE, LINGVAY, ILDIKO
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Semaglutide, a new GLP-1 analog for the treatment of T2D, showed significant and clinically meaningful reductions in HbA1c and body weight (BW) across the SUSTAIN clinical trial program. SUSTAIN 7 compared semaglutide vs. dulaglutide (both once weekly) head-to-head in subjects with T2D both as add-on on metformin over 40 weeks. This exploratory analysis assessed treatment effect of semaglutide 0.5 mg vs. dulaglutide 0.75 mg and semaglutide 1.0 mg vs. dulaglutide 1.5 mg by baseline BMI subgroups (
ISSN:0012-1797
1939-327X
DOI:10.2337/db18-1083-P